Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.
Good morning. It’s the last day of Pride Month. Here are some gay things I’ve enjoyed lately: the movie “Maddie’s Secret,” the new MUNA album, my gay pickup soccer group, and matcha lattes.
Conflict-of-interest concerns over FDA peptide panelists
Yesterday, the FDA published the names of eight new panelists who will serve on a committee advising the agency on the possibility of allowing compounding pharmacies to manufacture certain peptides. But STAT’s Lizzy Lawrence and Sarah Todd report that the majority of those new members are involved with businesses that promote and prescribe peptides — meaning they’ll be weighing in on rules changes that could directly benefit them.
“The key question seems to be whether this arguably ‘stacked’ [committee] will essentially overrule FDA staff who might continue to have concerns on a switch to listing of these peptides as permissible for compounding,” said Paul Knoepfler, a biologist and STAT contributor who wrote an essay this spring predicting a peptide committee overhaul. Read more from Lizzy and Sarah about the new members and their potential conflicts of interest.
